Cargando…

Meta-analysis of the benefit of sitagliptin treatment in patients with type 2 diabetes complicated with incipient nephropathy

The purpose of this meta-analysis was to evaluate the evidence of the clinical efficacy and safety of sitagliptin in diabetic patients with incipient nephropathy. PubMed, Ovid, Cochrane library, Chinese National Knowledge Infrastructure, and Wanfang databases were searched in September 2017 to ident...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Wei, Yu, Jiangyi, Yan, Qianhua, Wang, Lijuan, Li, Nan, Xiong, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122566/ https://www.ncbi.nlm.nih.gov/pubmed/30210604 http://dx.doi.org/10.3892/etm.2018.6449

Ejemplares similares

Meta-analysis of the efficacy of liraglutide in patients with type 2 diabetes accompanied by incipient nephropathy
por: Liu, Wei, et al.
Publicado: (2019)

Urinary Exosomal MicroRNAs in Incipient Diabetic Nephropathy
por: Barutta, Federica, et al.
Publicado: (2013)

Cost–benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2019)

Intestinal dysbiosis activates renal renin-angiotensin system contributing to incipient diabetic nephropathy
por: Lu, Chen Chen, et al.
Publicado: (2018)

iTRAQ plasma proteomics analysis for candidate biomarkers of type 2 incipient diabetic nephropathy
por: Lu, Hongmei, et al.
Publicado: (2019)

Evaluation of Paraoxonase, Arylesterase, and Homocysteine Thiolactonase Activities in Patients with Diabetes and Incipient Diabetes Nephropathy
por: Ayan, Durmuş, et al.
Publicado: (2019)

Sitagliptin ameliorates diabetic nephropathy by blocking TGF-β1/Smad signaling pathway
por: Wang, Dongdong, et al.
Publicado: (2018)

Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)
por: Mega, Cristina, et al.
Publicado: (2011)

Effect of sitagliptin on proteinuria in patients with type 2 diabetes – A renoprotective effect of sitagliptin
por: Narimani, Rouhollah, et al.
Publicado: (2021)

The Treatment of Incipient Insanity
Publicado: (1905)

The Treatment of Incipient Madness
Publicado: (1918)

The Treatment of Incipient Madness
por: Robertson, George M.
Publicado: (1918)

The Treatment of Incipient Insanity
por: Young, A. D.
Publicado: (1906)

Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury
por: Asakawa, Masahiro, et al.
Publicado: (2015)

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
por: Miller, Shannon A, et al.
Publicado: (2009)

Effect of sitagliptin combined with Yiqi yangyin huoxue decoction on clinical efficacy and hemorheology in early diabetic nephropathy
por: Ling, Jun, et al.
Publicado: (2023)

Diabetic nephropathy – complications and treatment
por: Lim, Andy KH
Publicado: (2014)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

Incipient Diabetes Treated with Long-Term Classical Prescription
por: Wei, Xiuxiu, et al.
Publicado: (2019)

Review of sitagliptin phosphate: a novel treatment for type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2007)

Pleiotropic Effects of Sitagliptin in the Treatment of Type 2 Diabetes Mellitus Patients
por: Kubota, Akira, et al.
Publicado: (2012)

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
por: Reynolds, Jonathan K
Publicado: (2009)

Effect of concomitant administration of coenzyme Q10 with sitagliptin on experimentally induced diabetic nephropathy in rats
por: Maheshwari, Rajesh, et al.
Publicado: (2016)

The Treatment of Epilepsy in Its Incipiency
por: Spratling, Wm. P.
Publicado: (1900)

Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients
por: Sun, Yue, et al.
Publicado: (2020)

Potential Therapeutic Benefits of Metformin Alone and in Combination with Sitagliptin in the Management of Type 2 Diabetes Patients with COVID-19
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2022)

The durability of sitagliptin in elderly patients with type 2 diabetes
por: Hsieh, Ching-Jung, et al.
Publicado: (2014)

Incipient Tuberculosis
Publicado: (1913)

Incipient Decay
Publicado: (1899)

Incipient Insanity
Publicado: (1923)

Incipient Insanity
por: Stroud, H. E.
Publicado: (1887)

Incipient Tuberculosis
Publicado: (1907)

PERS&O (PERsistent Sitagliptin treatment & Outcomes): observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment
por: Buonaiuto, Giulia, et al.
Publicado: (2016)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
por: Barnard, Karen, et al.
Publicado: (2010)

Paeoniflorin attenuates incipient diabetic nephropathy in streptozotocin-induced mice by the suppression of the Toll-like receptor-2 signaling pathway
por: Shao, Yun-xia, et al.
Publicado: (2017)

Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus
por: Mori, Hiroko, et al.
Publicado: (2013)

Efficacy and Safety of Sitagliptin in Japanese Patients With Type 2 Diabetes
por: Ohmura, Hirotoshi, et al.
Publicado: (2015)

Sitagliptin and oral cancer risk in type 2 diabetes patients
por: Tseng, Chin-Hsiao
Publicado: (2017)

Sitagliptin and heart failure hospitalization in patients with type 2 diabetes
por: Tseng, Chin-Hsiao
Publicado: (2016)

Safety and Efficacy of Sitagliptin-Metformin in Fixed Combination for the Treatment of Type 2 Diabetes Mellitus
por: Ballav, Chitrabhanu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_cq8oulrrcc0hop4bt3irt35e19